IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS

Torrent Pharmaceuticals Limited, et al,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	**No. 16 C 2988**
	)	
Daiichi Sankyo, Inc., et al,	)	**Judge Rebecca R. Pallmeyer**
	)	
	)	
Defendants.	)	

ORDER

On July 25, 2016, the court entered an order concluding that it lacks personal jurisdiction over Defendants Daiichi Sankyo, Inc. and Daiichi Sankyo Co., Ltd. The court directed the parties to show cause within 14 days why the case should not be dismissed in entirety without prejudice. Intervenor Mylan Pharmaceuticals, Inc., the only party to respond to the court's order, confirms that the case should be dismissed. It is so ordered; this case is dismissed without prejudice. Mylan's motion for judgment on the pleadings [54] and Torrent's motion for summary judgment [41] are stricken as moot.

ENTER:

Dated: October 3, 2016

REBECCA R. PALLMEYER
United States District Judge

A TRUE COPY ATTEST
THOMAS G. BRUTON, CLERK
By: s/ JESSICA J. RAMOS
DEPUTY CLERK
U.S. DISTRICT COURT, NORTHERN
DISTRICT OF ILLINOIS
January 12, 2017

AO 120 (Rev. 08/10)

TO:	Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court for the Northern District of Illinois on the following

☑ Trademarks or ☐ Patents. (☐ the patent action involves 35 U.S.C. § 292.):

DOCKET NO.	DATE FILED	U.S. DISTRICT COURT
1:16-cv-02988	3/9/2016	for the Northern District of Illinois

PLAINTIFF	DEFENDANT
Torrent Pharmaceuticals Limited et al	Daiichi Sankyo, Inc. et al

PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 (See Attached)		
2		
3		
4		
5		

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY ☐ Amendment ☐ Answer ☐ Cross Bill ☐ Other Pleading	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

CLERK	(BY) DEPUTY CLERK	DATE
Thomas G. Bruton	Jessica J. Ramos	1/12/2017

Copy 1—Upon initiation of action, mail this copy to Director **Copy 3—Upon termination of action, mail this copy to Director**
Copy 2—Upon filing document adding patent(s), mail this copy to Director **Copy 4—Case file copy**

US006878703B2

(12) **United States Patent**
Sada et al.

(10) **Patent No.: US 6,878,703 B2**
(45) **Date of Patent: Apr. 12, 2005**

(54) **PHARMACEUTICAL COMPOSITION**

(75) Inventors: **Toshio Sada**, Tokyo (JP); **Makoto Mizuno**, Funabashi (JP)

(73) Assignee: **Sankyo Company, Limited**, Tokyo (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/442,874**

(22) Filed: **May 20, 2003**

(65) **Prior Publication Data**

US 2004/0002529 A1 Jan. 1, 2004

Related U.S. Application Data

(63) Continuation of application No. PCT/JP01/10095, filed on Nov. 19, 2001.

(30) **Foreign Application Priority Data**

Nov. 21, 2000 (JP) 2000-354327
May 31, 2001 (JP) 2001-164009

(51) **Int. Cl.**[7] **A61K 31/54**; A61K 31/41
(52) **U.S. Cl.** **514/223.5**; 514/381
(58) **Field of Search** 514/223.5, 382, 514/381

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,554,816 A		5/1951	Clapp et al.	
2,783,241 A		2/1957	Young et al.	
2,835,702 A		5/1958	Schultz	
2,976,289 A		3/1961	Cohen et al.	
2,980,679 A		4/1961	Pala	
3,009,911 A		11/1961	McManus	
3,025,292 A		3/1962	Jones et al.	
3,055,904 A		9/1962	Graf et al.	
3,058,882 A		10/1962	Stürm et al.	
3,108,097 A		10/1963	Ugi	
3,163,645 A		12/1964	de Stevens et al.	
3,183,243 A		5/1965	Lee et al.	
3,254,076 A		5/1966	Lund et al.	
3,255,241 A		6/1966	Schultz et al.	
3,265,573 A		8/1966	Goldberg	
3,313,813 A		4/1967	Cragoe, Jr.	
3,356,692 A		12/1967	Horstmann et al.	
3,360,518 A		12/1967	Shetty	
3,567,777 A		3/1971	Liebenow	
3,634,583 A		1/1972	Feit	
3,758,506 A		9/1973	Godfroid et al.	
5,138,069 A		8/1992	Carini et al.	
5,153,197 A		10/1992	Carini et al.	
5,264,447 A	*	11/1993	Ohtawa	514/381
5,310,928 A		5/1994	Lo et al.	
5,616,599 A	*	4/1997	Yanagisawa et al.	514/381
5,656,650 A	*	8/1997	Weinstock	514/396

FOREIGN PATENT DOCUMENTS

BE	639386	10/1963
EP	0 400 835 A1	12/1990
EP	0 503 785 A1	9/1992
EP	0 733 366 A2	9/1996
GB	795174	5/1958
GB	851287	10/1960
WO	WO 89/06233 A1	7/1989

OTHER PUBLICATIONS

Krousel–Wood et al., "Primary Prevention of Essential Hypertension", Med. Clncs. of North Am., (Jan. 2004) 88(1) 223–38. (Abstract only).*

C.W. Whitehead et al., Diuretics, V, 3,4–Dihydro–1,2, 4–benzothiadiazine 1,1–Dioxides, *J. Org. Chem., 26,* (1961), pp. 2814–2818.

Stevens et al., *Experientia,* "The Chemistry and Pharmacology of Hydrotrichlorothiazide", 16, (1960), p. 113–114.

Close et al., "Synthesis of Potential Diuretic Agents. I. Derivatives of 7–Sulfamyl–3,4–dihydro–1,2,4–benzothiadiazine 1,1–Dioxide", *J. Am. Chem. Soc., 82,* (1960), pp. 1132–1135.

Jucker et al., "Über diuretisch wirksame Benzoesäure–D-erivate", *Helv. Chim. Acta., 45,* (1962), pp. 2316–2325.

(Continued)

Primary Examiner—Raymond J. Henley, III
(74) *Attorney, Agent, or Firm*—Frishauf, Holtz, Goodman & Chick, P.C.

(57) **ABSTRACT**

A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics:

(I)



The pharmaceutical composition of the present invention has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for preventing or treating hypertension or heart disease.

15 Claims, No Drawings